Status:
COMPLETED
A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Liver Transplantation
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The aim of this exploratory study is to evaluate the rejection rate in patients treated with cyclosporine (CsA) preceding oral administration of cyclosporine micro emulsion in de novo liver recipients...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- About to undergo a primary liver transplant (including living donor, split liver).
- Expected to be capable of study participation for full 6 months post-transplantation.
- Allograft biopsies will be possible.
- Exclusion Criteria
- The surgery is a multi-organ transplant.
- The patient has previously been transplanted with any other organ.
- The graft derives from a non-heart beating donor.
- Other protocol-defined inclusion/exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00332462
Start Date
May 1 2006
End Date
January 1 2009
Last Update
March 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational Site
Various Cities, Germany